InvestWiserEQL Pharma AB
EQL · Nasdaq Stockholm · Healthcare
23.40SEK
+3.1%last day
Price as of 2 October 2026
Performance
1 month
−11.7%
1 year
−64.5%
3 years, per year
–
5 years, per year
–
Largest fall, 3 years
−81.9%
Below the peak now
−78.5%
Volatility, 1 year
63.9%
Return with dividends reinvested.
Key figures
P/E
negative earnings
P/B
2.7
Dividend yield
0.0%
Return on equity
−4.3%
Net margin
−3.1%
Market value
69 m USD
Quality, value and trend
Where EQL Pharma stands against every Nordic stock today. 100 is best.
6
Profitability and a sound balance sheet over time. Better than 6% of Nordic stocks.
32
The price measured against earnings, assets and cash flow. Better than 32% of Nordic stocks.
13
The price development over the past year. Better than 13% of Nordic stocks.
3
Quality, value and trend together. Better than 3% of Nordic stocks.
About EQL Pharma
EQL Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 65 employees.
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis